RxDoctor Payments Data

Deanna Wright

Gynecology · Tahlequah, OKNPI 1144321456

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 54.3% of the total. Reporting peaked in 2023 at $526 and has fallen 76.1% since, to $125 in 2025.

$1,393in general payments, 2019–2025

Across 90 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$756
  • Amgen$134
  • AstraZeneca$90
  • Lilly USA, LLC$75
  • GSK$67
  • AbbVie$49
  • plus $220 from 12 others

What the payments were for

  • Food & beverage$1,38199%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$93,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$43,243
RybelsusSemaglutide23$42,890
EliquisApixaban33$41,810
TrulicityDulaglutide28$35,959
MyrbetriqMirabegron30$30,296
GemtesaVibegron24$18,235
LinzessLinaclotide13$16,559
BelsomraSuvorexant13$5,691
Estradiol101$5,618
Estradiol (Twice Weekly)Estradiol20$2,182
Omeprazole49$2,085
Risedronate Sodium12$1,317
Montelukast Sodium31$1,237
Levothyroxine Sodium120$1,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$756$136,09297 claims
GSKTrelegy Ellipta$67$43,24343 claims
Lilly USA, LLCTrulicity$75$35,95928 claims
Astellas Pharma US IncMyrbetriq$22$30,29630 claims
Sumitomo Pharma America, Inc.Gemtesa$20$18,23524 claims
AbbVieLinzess$49$16,55913 claims
MerckBelsomra$15$5,69113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gynecology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other gynecology in Tahlequah

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →